BCRX
BioCryst Pharmaceuticals Inc
$
8.300
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.450
Open
8.380
VWAP
8.34
Vol
1.82M
Mkt Cap
1.74B
Low
8.260
Amount
15.20M
EV/EBITDA(TTM)
38.65
Total Shares
206.38M
EV
2.22B
EV/OCF(TTM)
132.18
P/S(TTM)
3.18
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
158.11M
+8.64%
0.028
-121.73%
155.74M
+18.4%
0.034
-147.91%
162.24M
+38.57%
0.026
-143.05%
Estimates Revision
The market is revising Downward the revenue expectations for BioCryst Pharmaceuticals, Inc. (BCRX) for FY2025, with the revenue forecasts being adjusted by -0.88% over the past three months. During the same period, the stock price has changed by -16.75%.
Revenue Estimates for FY2025
Revise Downward
-0.88%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-26.47%
In Past 3 Month
Stock Price
Go Down
-16.75%
In Past 3 Month
12 Analyst Rating
101.81% Upside
Wall Street analysts forecast BCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCRX is 16.75 USD with a low forecast of 11.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
1 Hold
0 Sell
Strong Buy
101.81% Upside
Current: 8.300
Low
11.00
Averages
16.75
High
30.00
101.81% Upside
Current: 8.300
Low
11.00
Averages
16.75
High
30.00
BofA
Tazeen Ahmad
Buy
maintain
$13 -> $15
2025-06-30
Reason
BofA
Tazeen Ahmad
Price Target
$13 -> $15
2025-06-30
maintain
Buy
Reason
BofA analyst Tazeen Ahmad raised the firm's price target on BioCryst to $15 from $13 and keeps a Buy rating on the shares after the company announced an agreement to sell the European Orladeyo business to Neopharmed Gentili for up to $264M. The firm is "encouraged" by the deal given the majority of Orladeyo revenues are realized in the U.S. and it provides clear line of sight for settling outstanding debt, the analyst tells investors.
Wedbush
Outperform
maintain
$16 -> $18
2025-06-30
Reason
Wedbush
Price Target
$16 -> $18
2025-06-30
maintain
Outperform
Reason
Wedbush raised the firm's price target on BioCryst to $18 from $16 and keeps an Outperform rating on the shares as it sees the sale of the European Orladeyo business as a positive move for the company. The sale allows BioCryst to pay down existing debt in a non-dilutive manner. Additionally, lowering expenses also puts BioCryst in a better position to prioritize internal candidate advancement and/or business development opportunities, Wedbush adds. Overall, the firm sees BioCryst in a stronger position following completion of the deal.
RBC Capital
Brian Abrahams
Buy
Reiterates
$11
2025-04-11
Reason
RBC Capital
Brian Abrahams
Price Target
$11
2025-04-11
Reiterates
Buy
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$15
2025-04-10
Reason
Needham
Serge Belanger
Price Target
$15
2025-04-10
Reiterates
Strong Buy
Reason
Citizens Capital Markets
Jonathan Wolleben
Buy
Reiterates
$18
2025-03-03
Reason
Citizens Capital Markets
Jonathan Wolleben
Price Target
$18
2025-03-03
Reiterates
Buy
Reason
JMP Securities
Jonathan Wolleben
Buy
Reiterates
$18
2025-01-31
Reason
JMP Securities
Jonathan Wolleben
Price Target
$18
2025-01-31
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for BioCryst Pharmaceuticals Inc (BCRX.O) is 19.03, compared to its 5-year average forward P/E of -34.30. For a more detailed relative valuation and DCF analysis to assess BioCryst Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-34.30
Current PE
19.03
Overvalued PE
67.22
Undervalued PE
-135.81
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-9.83
Current EV/EBITDA
20.15
Overvalued EV/EBITDA
52.19
Undervalued EV/EBITDA
-71.85
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
7.93
Current PS
2.73
Overvalued PS
14.30
Undervalued PS
1.56
Financials
Annual
Quarterly
FY2025Q2
YoY :
+49.41%
163.35M
Total Revenue
FY2025Q2
YoY :
+239.98%
29.79M
Operating Profit
FY2025Q2
YoY :
-140.12%
5.09M
Net Income after Tax
FY2025Q2
YoY :
-133.33%
0.02
EPS - Diluted
FY2025Q2
YoY :
-2800.13%
41.12M
Free Cash Flow
FY2025Q2
YoY :
-0.12%
98.29
Gross Profit Margin - %
FY2025Q2
2.83
FCF Margin - %
FY2025Q2
YoY :
-126.83%
3.11
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
52.8K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
3.3M
Volume
2
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
109.7K
Volume
Months
6-9
3
2.9M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
52.8K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BCRX News & Events
Events Timeline
2025-08-04 (ET)
2025-08-04
07:05:10
BioCryst reaffirms FY25 ORLADEYO revenue view $580M-$600M
2025-08-04
07:04:08
BioCryst reports Q2 EPS 15c, consensus 3c
2025-07-31 (ET)
2025-07-31
07:13:23
BioCryst announces planned retirement of CEO Stonehouse, Gayer to succeed
Sign Up For More Events
Sign Up For More Events
News
4.0
08-04BenzingaNeedham Maintains Buy on BioCryst Pharma, Maintains $17 Price Target
3.0
08-03SeekingAlphaHere are the major earnings before the open Monday
5.0
07-31NewsfilterBioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
Sign Up For More News
People Also Watch
FAQ
What is BioCryst Pharmaceuticals Inc (BCRX) stock price today?
The current price of BCRX is 8.3 USD — it has decreased -0.6 % in the last trading day.
What is BioCryst Pharmaceuticals Inc (BCRX)'s business?
What is the price predicton of BCRX Stock?
What is BioCryst Pharmaceuticals Inc (BCRX)'s revenue for the last quarter?
What is BioCryst Pharmaceuticals Inc (BCRX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for BioCryst Pharmaceuticals Inc (BCRX)'s fundamentals?
How many employees does BioCryst Pharmaceuticals Inc (BCRX). have?